Should You Buy Vertex Before Feb. 12?
Vertex Pharmaceuticals (NASDAQ: VRTX) has underperformed the market over the past year, rising less than 2%. The biotech, known for its cystic fibrosis (CF) treatments, is scheduled to report earnings on Feb. 12. While there's never just one good time to buy a stock, here's a look at whether investors should buy the pharmaceutical stock before that date.
The company reported third-quarter earnings on Nov. 3. Revenue was up 11% year over year to $3.08 billion. However, earnings per share (EPS) rose only 4.7% to $4.20 as increased research and development expenses offset some of the revenue growth.
Investors did not react well to the report. The stock dropped more than 1% on the day earnings were announced and continued to fall by more than 3% over the next few days, mainly because sales of some of its newer therapies were underwhelming.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Klare Kaufstimmung: Vertex Pharmaceuticals Inc. hat 39 Buy-Einschätzungen und keine Sell-Einschätzung.
Ein Kursziel von 455 € für Vertex Pharmaceuticals Inc. impliziert ein leicht positives Wachstum gegenüber dem aktuellen Kurs von 414.05 €.
